Drozitumab

Drug Profile

Drozitumab

Alternative Names: Anti-Death Receptor 5 monoclonal antibody - Genentech; Anti-DR5 mAb - Genentech; Anti-TRAIL Receptor-2 monoclonal antibody - Genentech; Apomab; PRO-95780; RG7425

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Chondrosarcoma; Colorectal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 05 Jun 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events, pharmacokinetics, and Cancer therapeutic trials sections
  • 03 Jun 2007 Phase-II clinical trials in Non-Hodgkin's lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top